Chemotherapy wafers for high grade glioma

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 3, 2011, Pages

  Hart, Michael G ^a   Garside, Ruth ^b   Rogers, Gabriel ^c   Somerville, Margaret ^d   Stein, Ken ^b   Grant, Robin ^e  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^d PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; PLACEBO; ALKYLATING AGENT; DECANEDIOIC ACID 4,4' (1,3 PROPANEDIYLBIS(OXY))BIS(BENZOIC ACID) COPOLYMER; DECANEDIOIC ACID-4,4'-(1,3-PROPANEDIYLBIS(OXY))BIS(BENZOIC ACID) COPOLYMER; DECANOIC ACID DERIVATIVE; DRUG CARRIER; POLYESTER;

BRAIN EDEMA; BRAIN SURGERY; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; GLIOMA; HUMAN; INFECTION; INTRACRANIAL HYPERTENSION; META ANALYSIS; NEURONAVIGATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT; BRAIN TUMOR; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; COMBINED MODALITY THERAPY; DECANOIC ACIDS; DRUG CARRIERS; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; POLYESTERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79953273588     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007294.pub2     Document Type: Review

References (50)

1. Brem H, Piantadosi S, Burger PC. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrence. The Lancet 1995;345:1008-12.
2. Valtonen S, Timonen U, Toivanen P. Interstitial Chemotherapy with Carmustine-loaded Polymers for High-grade Gliomas: A Randomized Double-blind Study. Neurosurgery 1997;41(1):44-8.
3. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
4. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicentre controlled trial. Acta Neurochirurgica 2006;148:269-275.
5. Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, Sisti M. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. Journal of Neuro-oncology 1995;26:111-23.
6. Brophy J, Chen J. Use of carmustine implants (GLIADEL wafer) in patients with malignant glioma at The McGill University Health Centre. Technology Assessment Unity of the McGill University Health Centre 2004.
7. Dalbasti T, Oktar N, Cagli S, Ozdamar N. Local interstitial chemotherapy with sustained release bucladesine in de novo glioblastoma multiforme: a preliminary study. Journal of Neuro-Oncology 2002;56:167-174.
8. US Food, Drug Administration. Approval Package: Gliadel Wafer (20-637/S16). http://www.fda.gov. [: http://www.fda.gov.cder/foi/nda/2003/20-637x016_Gliadel.htm]
9. Garside R. Pitt M. Anderson R. Rogers G. Dyer M. Mealing S, et al.The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.. Health Technology Assessment (Winchester, England) 2007;11(45):iii-iv, ix-221.
10. Kleinberg LR, Weingart J, Burger P, Carson K, Grossman SA, Li K, et al.Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Investigation 2004;22:1-9.
11. La Rocca RV, Hodes J, Villanueva WG, Vitaz TW, Morassutti DJ, Doyle MJ, et al.A Phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients with newly diagnosed supratentorial high-grade malignant glioma who have undergone surgery with carmustine (BCNU) wafer insertion. Neuro-oncology 2007;8:391-500.
12. Mulrow M. Long term efficacy of the Gliadel (R) wafer in patients with high-grade malignant gliomas: A meta analysis. 12 European Congress of Neurosurgery. 2003:513-516.
13. Perry J. Chambers A. Spithoff K. Laperriere N. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current Oncology 2007;14(5):189-94.
14. Sheleg SV, Korotkevich EA, Zhavrid EA. Local chemotherapy with cisplatin-depot for glioblastoma multiforme. Journal of Neuro-oncology 2004;60:53-59.
15. Castillo MS, FG Davis, Surawicz T, Bruner JM, Bigner S, Coons S, et al.Consistency of Primary Brain Tumor Diagnoses and Codes in Cancer Surveillance Systems. Neuroepidemiology 2004;23:85-93.
16. Counsell CE, Collie DA, Grant R. Incidence of intracranial tumours in the Lothian region of Scotland, 1989-90. Journal of Neurology, Neurosurgery & Psychiatry 1996;61(2):143-50.
17. Centre for Reviews and Dissemintation. Systematic Reviews: CRD's guidance for undertaking reviews in health care. York: York Publishing Services Limited, 2009.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
19. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy and survival in malignant glial neoplasms. Journal of Neurosurgery 1993;78:767-75.
20. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clinical Pharmacokinetics 2002;41(6):403-19.
21. Fowkes FGR, Fulton PM. Critical appraisal of published research: introductory guidelines. British Medical Journal 1991;302:1136-40.
22. Gallego JM, Barcia JA, Barcia-Marino C. Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta Neurochir (Wien) 2007;149:261-65.
23. Glioma Meta-Analysts Trialists (GMT) Group. Chemotherapy for High Grade Glioma. Cochrane Database of Systematic Reviews 2002, Issue Issue 3. Art. No.: CD003913. DOI: 10.1002/14651858. [DOI: 10.1002/14651858]
24. Grant R. Overview: Brain Tumour Diagnosis and Management/Royal College of Physicians Guidelines. Journal of Neurology, Neurosurgery and Psychiatry 2004;75(Suppl II):ii18-ii23.
25. Hart MG, Grant R, Metcalfe SE. Biopsy versus resection for High Grade Glioma. Cochrane Database of Systematic Reviews 2000, Issue Issue 2. Art. No.: CD002034. DOI: 10.1002/14651858. [DOI: 10.1002/14651858]
26. Hensen JW, Ulmer S, Harris GJ. Brain Tumour Imaging in Clinical Trials. American Journal of Neuroradiology 2008;29:419-24.
27. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2.[updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
28. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30:907-11.
29. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
30. Kaal ECA, Vecht CJ. The management of brain edema in brain tumour. Current Opinion in Oncology 2004;16:593-600.
31. Karnofsky DA. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634-56.
32. Kim L, Glantz M. Chemotherapeutic option for primary brain tumours. Current treatment options in oncology 2006;7:467-78.
33. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathology 1993;3(3):255-68.
34. Kreth FW, Warnke PC, Scheremet R, Ostertag CB. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. Journal of Neurosurgery 1993;78:762-6.
35. Mauer ME, Bottomley A, Taphoorn MJB. Evaluating health-related quality of life and symptom burden in brain tumour patients: instruments for use in clinical trials and clinical practice. Current Opinion in Neurology 2008;21:741-53.
36. Medical Dictionary for Regulatory Authorities. http://www.meddramsso.com/MSSOWeb/index.htm.
37. Nazzaro J, Neuwelt E. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. Journal of Neurosurgery 1990;73:331-4.
38. National Collaborating Centre for Cancer. Improving Outcomes for People with Brain and Other CNS Tumours: The Evidence Review. http://www.nice.org.uk/guidance/index.jsp?action=download&o=28963.
39. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature of endpoints. Statistics in Medicine 1998;17:2815-34.
40. Rampling R, James A, Papanastassoiu V. The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy. Journal of Neurology, Neurosurgery and Psychiatry 2005;75(Suppl II):ii24-ii30.
41. Scottish Health Statistics: Brain and central nervous system cancer, 2009. ISD Scotland; http://www.isdscotland.org/isd/1395.htm.
42. Siker ML, Chakravarti A, Mehta MP. Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?. Critical reviews in Oncology-Haematology 2006;60(2):99-111.
43. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.. Lancet 2002;359:1011-8.
44. Stupp R, Mason WP, van den Bent MJ. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups. National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.. New England Journal of Medicine 2005;352:987-96.
45. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al.Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. Journal of Neurosurgery 1978;49:333-43.
46. Weber EL, Goebel EA. Cerebral oedema associated with Gliadel wafers: Two case studies. Neuro-oncology 2005;7:84-89.
47. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al.Updated Response Assessment Criteria in High Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology 2010;28(10):1963-72.
48. Whittle IR, Lyles S, Walker M. Gliadel therapy given for first resection of malignant glioma: a single centre study of the potential use of Gliadel. Journal of Neurosurgery 2003;17:352-4.
49. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982;5:649-655.
50. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. Journal of Neurosurgery 1989;71(4):487-93.